Omada Health reports preliminary Q4 and FY 2025 revenue figures

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Omada Health, a digital health provider focused on chronic-disease prevention and care, reported preliminary, unaudited revenue results for the fourth quarter and full fiscal year ending December 31, 2025. The company said preliminary revenue for Q4 2025 is approximately US $67 million, up from US $62 million in Q4 2024, reflecting continued demand for its virtual programs addressing conditions such as diabetes, hypertension and musculoskeletal disorders. For the full year, preliminary unaudited revenue is expected to be approximately US $246 million, an increase from US $228 million in FY 2024, driven by expanded payer and employer engagements and increased utilization of its digital therapeutic offerings.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE